Indivior (LON:INDV) touted data today from its pivotal Phase III trial for RBP-6000, a once-monthly injectable buprenorphine depot for the treatment of adults with opioid use disorder.
The 24-week study met its primary and key secondary endpoints for both dosage regimens, according to the company.
Get the full story at our sister site, Drug Delivery Business News.
The post Indivior touts late-stage trial for monthly buprenorphine depot appeared first on MassDevice.